Compound ID | 1017

Meonomycin complex C

Class: Moenomycin

Spectrum of activity: Gram-positive
Details of activity: Direct inhibition of peptidoglycan glycosyltransferases.
Propensity to select resistant mutants: Yes
Year first mentioned: 1965
Highest developmental phase: Preclinical
Development status: Inactive
Chemical structure(s):
Click here for structure editor
Molecular weight: 1407.4
Iso. SMILES: C[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2O)NC(=O)C)O[C@@H]3[C@H]([C@H]([C@H](O[C@@H]3OP(=O)(O)OC[C@H](C(=O)O)OC/C=C(\C)/CC/C=C/C(C)(C)CCC(=C)C/C=C(\C)/CCC=C(C)C)C(=O)O)O)OC(=O)N)CO)NC(=O)C)O)O[C@H]4[C@@H]([C@H]([C@H]([C@H](O4)C(=O)NC5=C(CCC5=O)O)O)O)O
InChI Key: ZEZYCFPDLMTORO-DKZCLELOSA-N
Can. SMILES: CC(=CCC/C(=C/CC(=C)CCC(C)(C)/C=C/CC/C(=C/CO[C@H](COP(=O)(O)O[C@@H]1[C@@H]([C@H]([C@H]([C@@H](C(=O)O)O1)O)OC(=O)N)O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](CO)O2)O[C@H]3[C@@H]([C@H]([C@@H]([C@@H](C)O3)O[C@H]4[C@@H]([C@H]([C@H]([C@@H](C(=O)NC5=C(CCC5=O)O)O4)O)O)O)O)NC(=O)C)O)NC(=O)C)C(=O)O)/C)/C)C
InChI: InChI=1S/C62H95N4O30P/c1-28(2)14-13-16-29(3)17-18-31(5)21-24-62(9,10)23-12-11-15-30(4)22-25-86-38(55(79)80)27-87-97(84,85)96-60-53(50(95-61(63)83)47(77)52(93-60)56(81)82)94-58-41(65-34(8)69)43(73)49(37(26-67)89-58)91-57-40(64-33(7)68)42(72)48(32(6)88-57)90-59-46(76)44(74)45(75)51(92-59)54(78)66-39-35(70)19-20-36(39)71/h12,14,17,22-23,32,37-38,40-53,57-60,67,70,72-77H,5,11,13,15-16,18-21,24-27H2,1-4,6-10H3,(H2,63,83)(H,64,68)(H,65,69)(H,66,78)(H,79,80)(H,81,82)(H,84,85)/b23-12+,29-17+,30-22+/t32-,37-,38-,40-,41-,42-,43-,44+,45-,46-,47-,48-,49-,50+,51+,52+,53-,57+,58+,59-,60-/m1/s1
External links:
PubChem link: https://pubchem.ncbi.nlm.nih.gov/compound/76971782
Citation:

AntibioticDB is supported by GARDP.

If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.